主页 > 医药科学 >
【medical-news】逆转化疗抵抗的新方法
Case Western Reserve University Licenses Methoxyamine To Tracon: New Therapy Reverses Resistance To Chemotherapy
Case Western Reserve University's Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a "first in class" drug that targets a specific DNA repair pathway.
TRACON Pharmaceuticals is an emerging biotechnology company focused on identifying, developing and commercializing targeted therapies for cancer and angiogenesis. TRACON's management team couples their ability to execute with their extensive knowledge of oncology drug development and first generation targeted therapies, enabling them to advance the development of next generation cancer therapies.
Methoxyamine was developed by University Hospitals Case Medical Center researchers Stanton Gerson, M.D., director of the National Cancer Institute-designated Case Comprehensive Cancer Center and University Hospitals Ireland Cancer Center, and Lili Lui, Ph.D., assistant professor of medicine in the department of hematology and oncology at the Case School of Medicine. They were the first to show the therapeutic potential of Methoxyamine as an anti-cancer drug in combination with other agents.
"We are very excited about the potential of this new drug. The promise of overcoming a major mechanism of drug resistance in cancer is terrific news for many patients. We see potential applications in patients with brain cancers, melanoma, lung cancer and leukemias and perhaps other cancers," said Gerson.
Under the licensing agreement, TRACON will develop and manage clinical trials of Methoxyamine. "We are excited to be able to develop Methoxyamine. Chemotherapy represents the most commonly used class of agents to treat cancer patients. Unfortunately, resistance of cancer cells to chemotherapy prevents many patients from benefiting. Methoxyamine's unique ability to reverse resistance to chemotherapy could improve the lives of the many patients treated with chemotherapy each year," noted Charles Theuer, M.D., Ph.D., president and CEO of TRACON.
Research for this new therapeutic evolved from the researchers' project in the National Institutes of Health Rapid Access to Interventional Development (RAID) program that provides researchers resources and support needed for the development of new therapeutics. The NIH RAID program focuses on a subset of small molecules, including new agents that improve the activity of established chemotherapeutics.
The patented therapy, which has been licensed to TRACON, has been studied most intensively in combination with the approved chemotherapeutic Temozolomide. Methoxyamine prevents cancer cells from repairing DNA damage caused by chemotherapy, according to Steve Tan, a senior licensing manager in Case's Tech Transfer Office.
According to Michael Haag, director of biomedical licensing in Case's Tech Transfer Office, Methoxyamine could improve the anti-cancer activity of many chemotherapeutic agents, including those used for solid tumors and hematologic malignancies. 没人翻译我来翻，上午发了，晚上怎没了，再发一遍。但整理稿没了，因没保存
Case Western Reserve University Licenses Methoxyamine To Tracon: New Therapy Reverses Resistance To Chemotherapy
美国凯斯西储大学批准甲氧胺转让给Tracon用于逆转化疗耐药的新尝试。
Case Western Reserve University's Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a "first in class" drug that targets a specific DNA repair pathway.
美国凯斯西储大学技术转让办公室与与加利福尼亚圣地亚哥TRACON 药厂签署了世界上独家技术许可开发甲氧胺作为肿瘤化疗耐药逆转剂的协议。
TRACON Pharmaceuticals is an emerging biotechnology company focused on identifying, developing and commercializing targeted therapies for cancer and angiogenesis. TRACON's management team couples their ability to execute with their extensive knowledge of oncology drug development and first generation targeted therapies, enabling them to advance the development of next generation cancer therapies.
TRACON是一个新兴的生物技术公司，主要进行癌症、血管生成靶向治疗药物的开发。
Methoxyamine was developed by University Hospitals Case Medical Center researchers Stanton Gerson, M.D., director of the National Cancer Institute-designated Case Comprehensive Cancer Center and University Hospitals Ireland Cancer Center, and Lili Lui, Ph.D., assistant professor of medicine in the department of hematology and oncology at the Case School of Medicine. They were the first to show the therapeutic potential of Methoxyamine as an anti-cancer drug in combination with other agents.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-10 05:11
医学,生命科学网